Genomics

Dataset Information

MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancer [ATAC-seq]


ABSTRACT: MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancer [ATAC-seq]

PROVIDER: PRJNA1130940 | ENA |

REPOSITORIES: ENA